Eli Lilly annual profit outlook tops expectations; stock gains
Investing.com - Eli Lilly's (NYSE: LLY) full-year profit forecast largely surpassed Wall Street expectations on Thursday, as the drugmaker targets expansion of its weight-loss treatments, sending shares higher. At 10:59 AM ET, Eli Lilly's stock was up 3.2%.
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...
Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...
Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...
Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...
Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.
Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.
Yahoo Finance Anchor Josh Lipton recaps the top stories on Wall Street as part of today's Market Minute. US stocks (^DJI, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback